Review Article | Volume 1 Issue 1 (2025) | Published in 0000-00-00
Association of certain HLA alleles, IL-6 and Estrogen levels as immunogenetic factors with incidence of ovarian cysts
-
Abstract
Background and Aim: Ovarian cyst syndrome, as a common female endocrinal defect at age of reproduction, it is a heterogeneous condition accompanied by clinical symptoms, including reproductive, cardio metabolic, and psychological disorders results in various diseases as consequences of immune system dysfunction, a recent study have reported that immunological mechanisms are involved in the development of ovarian syndrome. Patients with ovarian cysts have been found to be under a chronic but low-grade inflammatory status, including high levels of leukocytes, and disorder of endothelial, and pro- inflammatory cytokines. To detect any possible relation between genetic factors and immune response and hormone levels with incidence of ovarian cyst
Material and Method: a whole blood samples from 33 adult females with ovarian cysts for HLA typing by( SSO PCR) with( Auto-Lipa ) (automatic line probe assay) compared with another 20 healthy control samples .Serum samples from the same patients and control groups were used for estimation of the IL-6 and Estrogen levels by ELISA test.
Results; Genotyping of HLA region revealed a significant increase in frequency of certain alleles, *0320 and *0701 alleles showed significant P value 0.020, *730 allele with p value 0.05.IL-6 levels revealed an increase in patients group, compared to healthy control groups. Oslo estrogen levels increased in patients group compared to control group.
Conclusions: There is a significant variation in various parameters between ovarian cyst patients and healthy control groups, and this indicate a serious impact of these parameters in incidence of the disease.
-
References
[1] Allahbadia, G. N. and Merchant, R. (2010) polycystic ovary syndrome and impact on health. Middle East Fertil Soc J. (in press).
[2] Carmina, E., Oberfield, S. E. and Lobo, R. A. (2010) the diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol., 203: 201.e1-201.e5.
[3] Pasquali, R. and Gambineri, A. (2007). Polycystic ovary syndrome. Ann. N. Y. Acad. Sci., 1092:158-174.
[4] Acien, P. (2009) Criteria for the polycystic ovary syndrome. Fertil.Steril. 92: 1.
[5] Franks, S. (2009) polycystic ovary syndrome. Medicine, 37: 441-444.
[6] Ad’hiah, A. H. (2009). Distribution of HLA polymorphism in a sample of Iraqi Arabs in comparison with three Arab Gulf populations. Iraqi Journal of Science, 50: 120-125.
[7] Lin, A., Yan, W. H., Xu, H., Gan, M. F., Cai, J. F., Zhu M. and Zhou, M.Y. (2007) HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann. Oncol., 18: 1804-1809.
[8] Traherne, J. A. (2008) Human MHC architecture and evolution: implication for disease association studies. Int. J. Immunpgenet., 35: 179-192.
[9] Kaibe, M., Takakuwa, K., Murakawa, H., Ishii. K., Tamura. M. and Tanaka, K. (2006) Studies on the human leukocyte antigens in patients with polycystic ovary syndrome in a Japanese population: possible susceptibility of HLA-A11 and - DRB1*0403 to patient population with polycystic ovary syndrome. Am. J. Reprod. Immunol., 55: 301-306.
[10] Angstwurm MW, Gartner R, Ziegler-Heitbrock HW. Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine 1997; 9:370-4.
[11] Niccol i G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Bacà M, Pazzano V, Gangale MF, Tropea A, Crea F. CD4+CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril 2011; 95(8):2651-4.
[12] Petrı´kova J & Lazu´rova I. Ovarian failure and polycystic ovary syndrome. Autoimmunity Reviews 2012 11 A471-A478. (doi:10.1016/ j. autrev.2011.11.010)
[13] Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD & Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive of Biology and Endocrinology 2013 11 56–70. (Doi: 10.1186/1477-7827-11-56)
[14] Kelleher CM, Goldstein AM. Adnexal masses in children and adolescents. Clin Obstet Gynecol. 2015 Mar;58(1):76-92. [PubMed]
[15] American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5): e210-e226. [PubMed]
[16] American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins— Gynecology (2016): Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol., 128 (5): e210-e226.
[17] Luxman D, Bergman A, Sagi J, David MP. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol 1991; 77(S): 726-72
[18] McDonald JM, Modesitt SC (2006): The incidental postmenopausal adnexal mass. Clin Obstet Gynecol.,49(3):506-16.
[19] Bottomley C, Bourne T(2009): Diagnosis and management of ovarian cyst accidents. Best Pract Res Clin Obstet Gynaecol. , 23(5):711-24.
[20] Xu J, Shao H, Yang Y, Shi X, Tao M. Improvement and effect of stress responses and ovarian reserve function in patients with ovarian cysts after laparoscopic surgery. J Int Med Res. 2019;47(7):3212–3222. doi:10.1177/0300060519851333
[21] Abrahamsson G, Ekerhovd E, Janson PO, et al. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: clinical and experimental observations. Acta Obst Gynecol Scandi. 2020;99(10):1297–1302. doi:10.1111/aogs.13869
[22] Gordon JL, Girdler SS, Meltzer-Brody SE, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am J Psych. 2015;172(3):227–236. doi: 10.1176/appi.ajp.2014.1407091
[23] Velez LM, Seldin M, Motta AB. Inflammation and reproductive function in women with polycystic ovary syndrome†. Biol Reprod. 2021;104(6):1205–1217. doi:10.1093/biolre/ioab050
[24] Wethof C, Gollub E, Pate1 J. Ca 125 levels in menopausal women. Obstet Gynecol 1990, 76: 428-432.
[25] Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Endocrinol (Lausanne), 11 (2020), p. 440
[26] A.damska, A. Łebkowska, A. Krentowska, J. Hryniewicka, M. Adamski, M. Leśniewska, A.M. Polak, I. Kowalska Ovarian Reserve and Serum Concentration of Thyroid Peroxidase Antibodies in Euthyroid Women With Different Polycystic Ovary Syndrome Phenotypes Front
[27] *M. Menon, V. Ramachandran Antithyroid Peroxidase Antibodies in Women with Polycystic Ovary Syndrome J Obstet Gynaecol India, 67 (1) (2017), pp. 61-65
[28] Roszkowski, P. I, Sankowska, M., Jalbrzykowska, A., Radomski, D.,Dragowska,K
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 The AuthorsHow to cite
10.3390/ani15040592